Literature DB >> 7685405

Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

M Thali1, J P Moore, C Furman, M Charles, D D Ho, J Robinson, J Sodroski.   

Abstract

Interaction with the CD4 receptor enhances the exposure on the human immunodeficiency type 1 gp120 exterior envelope glycoprotein of conserved, conformation-dependent epitopes recognized by the 17b and 48d neutralizing monoclonal antibodies. The 17b and 48d antibodies compete with anti-CD4 binding antibodies such as 15e or 21h, which recognize discontinuous gp120 sequences near the CD4 binding region. To characterize the 17b and 48d epitopes, a panel of human immunodeficiency virus type 1 gp120 mutants was tested for recognition by these antibodies in the absence or presence of soluble CD4. Single amino acid changes in five discontinuous, conserved, and generally hydrophobic regions of the gp120 glycoprotein resulted in decreased recognition and neutralization by the 17b and 48d antibodies. Some of these regions overlap those previously shown to be important for binding of the 15e and 21h antibodies or for CD4 binding. These results suggest that discontinuous, conserved epitopes proximal to the binding sites for both CD4 and anti-CD4 binding antibodies become better exposed upon CD4 binding and can serve as targets for neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685405      PMCID: PMC237765     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

2.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

3.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Characterization of HIV-1 neutralization escape mutants.

Authors:  J A McKeating; J Gow; J Goudsmit; L H Pearl; C Mulder; R A Weiss
Journal:  AIDS       Date:  1989-12       Impact factor: 4.177

5.  Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Authors:  T K Hart; R Kirsh; H Ellens; R W Sweet; D M Lambert; S R Petteway; J Leary; P J Bugelski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.

Authors:  E Helseth; U Olshevsky; C Furman; J Sodroski
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Authors:  K Javaherian; A J Langlois; G J LaRosa; A T Profy; D P Bolognesi; W C Herlihy; S D Putney; T J Matthews
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

8.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein.

Authors:  P L Earl; B Moss; R W Doms
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

9.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

10.  Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.

Authors:  I Berkower; G E Smith; C Giri; D Murphy
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  376 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes.

Authors:  Y Yamaguchi-Kabata; T Gojobori
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.

Authors:  A L Edinger; C Blanpain; K J Kunstman; S M Wolinsky; M Parmentier; R W Doms
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

8.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

10.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.